Literature DB >> 8119268

Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate.

D F Welty1, G P Schielke, M G Vartanian, C P Taylor.   

Abstract

The concentration-time profile of [14C]gabapentin (GBP) in plasma and brain interstitial fluid (ISF) was determined following a single 15 mg/kg intravenous bolus dose to rats. Brain ISF was sampled with a microdialysis probe in striatum. Blood was also collected serially to 4 h postdose. At termination, brain was sectioned into regions and [14C]GBP concentrations were determined. Anticonvulsant effects were determined by maximal electroshock in rats with identical dosing. Plasma [14C]GBP declined linearly after dosing while brain ISF [14C]GBP concentration peaked at approximately 1 h and then declined in parallel with plasma concentration. Throughout, brain ISF [14C]GBP concentration was approximately 3-6% of [14C]GBP concentration in plasma. However, at 4 h postdose, whole brain tissue [14C]GBP concentration was equal to or greater than the concentration of [14C]GBP in plasma. Maximal anticonvulsant effect lagged behind both plasma and brain ISF GBP concentrations. The anticonvulsant effect of GBP is delayed by time-dependent events other than distribution from blood to brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119268     DOI: 10.1016/0920-1211(93)90078-l

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  19 in total

1.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

2.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

3.  Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method.

Authors:  M Hammarlund-Udenaes; L K Paalzow; E C de Lange
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 4.  Application of microdialysis in pharmacokinetic studies.

Authors:  W F Elmquist; R J Sawchuk
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

5.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

6.  Brain microdialysis and PK/PD correlation of pregabalin in rats.

Authors:  M R Feng; D Turluck; J Burleigh; R Lister; C Fan; A Middlebrook; C Taylor; T Su
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jan-Jun       Impact factor: 2.441

7.  Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.

Authors:  Malte Selch Larsen; Ron Keizer; Gordon Munro; Arne Mørk; René Holm; Rada Savic; Mads Kreilgaard
Journal:  Pharm Res       Date:  2016-01-15       Impact factor: 4.200

8.  Gabapentin suppresses cortical spreading depression susceptibility.

Authors:  Ulrike Hoffmann; Ergin Dileköz; Chiho Kudo; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-30       Impact factor: 6.200

Review 9.  Predictive validity of behavioural animal models for chronic pain.

Authors:  Odd-Geir Berge
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of norfloxacin in rats.

Authors:  Marylore Chenel; Agnès Barbot; Antoine Dupuis; Olivier Mimoz; Joël Paquereau; Serge Bouquet; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.